Inovia Bio Launches InovaMine to Accelerate Drug Development

LONDON, Nov. 5, 2026 /CourierPR/ -- Inovia Bio, a technology company specializing in AI platforms for drug development, has launched InovaMine, an end-to-end biostatistics and data pipeline platform. The new tool aims to accelerate clinical data analysis and drug development by streamlining the process of generating tables, listings, and figures from statistical analysis plans (SAPs).

InovaMine can handle both interventional trial data and longitudinal real-world data from various sources, including hospital records, claims data, electronic health records (EHRs), and registries. The platform harmonizes these diverse data sources into common models, ensuring consistency and reproducibility in the analysis.

The platform's workflow begins with the ingestion of a dataset and an SAP. Once the data is locked, producing the first set of tables takes weeks due to the need for programming and validation. However, subsequent questions, such as new subgroups or sensitivity analyses, can be addressed in hours, thanks to the pre-existing ingestion pipelines, data quality tests, and analysis code. This significantly reduces the time required for follow-up analyses, allowing teams to explore a wider range of questions and potentially uncover valuable insights that were previously unaffordable.

For emerging biotech companies, InovaMine opens up the possibility of conducting evidence programs beyond the primary study. Pharmaceutical sponsors can now perform subgroup and sensitivity analyses in days rather than waiting for the following quarter.

InovaMine's design prioritizes regulatory reproducibility. Every number in the tables can be traced back to the SAP line that specified it, the derivation that produced it, the cohort rule that admitted each patient, and the source record. Thousands of automated tests run on every data load, transformation, and output, ensuring a reproducible record of how each result was calculated. This feature is particularly valuable for sponsors, as regulators focus on whether the analysis followed the SAP and whether the results can be shown.

The platform is built to support the needs of both biotech and pharmaceutical sponsors worldwide. Inovia Bio's mission is to help these organizations move therapies forward faster by turning months of work into days. The company's focus on efficiency and innovation positions InovaMine as a key tool in the evolving landscape of drug development.

InovaMine is currently available to biotech and pharmaceutical sponsors, offering a powerful solution for accelerating drug development processes. With its ability to handle complex data and generate results quickly, the platform is poised to revolutionize the way clinical data is analyzed and utilized in the drug development process.